Bayer has announced a major investment of 2.2 billion dollars (1.95 billion euros) in a new pharmaceutical manufacturing site in New Albany, Ohio. The company said in a press release that this investment is part of a larger effort, adding to more than 7 billion dollars spent over the past five years on pharmaceutical research, development, and production in the United States. The first phase of the site is expected to begin operations in 2031, with a second phase starting in 2034. Bayer's CEO, Bill Anderson, called the investment "historic" and emphasized the importance of the U.S. as a key production base and innovation hub for the company. The U.S. government, under former President Donald Trump, has implemented tariffs on certain patented medicines made overseas and plans to introduce taxes on imported generic drugs beginning in 2028. These policies aim to encourage more pharmaceutical production within the United States. Companies that choose to build manufacturing facilities in the U.S. may qualify for lower tax rates compared to those that rely on imported products. The New Albany site will focus on producing medicines for the treatment of cancer, heart disease, and kidney disease. Bayer is not only a major player in the pharmaceutical industry but also one of the leading manufacturers of agricultural chemicals. The company stated that the new site in New Albany will create approximately 600 "high-value-added" jobs, which are typically well-paying and require specialized skills. In addition to these positions, the construction of the plant is expected to generate around 1,500 temporary jobs in the construction sector. The investment underscores Bayer's long-term commitment to the U.S. market and aligns with broader government efforts to boost domestic pharmaceutical manufacturing. The site is expected to contribute significantly to local and national economies, supporting both the healthcare and construction industries. With the first phase set to begin operations in 2031, the project represents a major step in Bayer's strategy to strengthen its presence in the United States.